China Shineway Pharmaceutical (2877.HK) - Strong Growth Momentum Is Expected to Continue in 2023
731 Views11 Apr 2023 08:55
Shineway’s 2022 performance was outstanding. As its TCM formula granules business would seize more market share, Shineway will keep high growth in 2023. It's undervalued considering large cash balance
Boomeranged on Fri, 4 Aug 2023 09:49
Shineway released positive profit alert for 23H1. The peak of COVID infection in 22Q1/23Q1 increased the demand for TCM products. Although TCM formula granules business is another driver to offset the slowdown of COVID related TCM after pandemic is under control, ensuring strong overall growth in 2023, the growth in 23H2 could slowdown. So, profit-taking is a good idea when valuation isn't cheap.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Shineway Pharmaceutical (2877.HK) 23Q1 - Growth Is Likely to Slow in Coming Quarters11 May 2023
- Valuation System with Chinese Characteristics – the Correct Interpretation and Its Deep Meaning10 May 2023
- China Traditional Chinese Medicine (570.HK) - Looking Forward to a Performance Turnaround in 202312 Apr 2023
- China Traditional Chinese Medicine (TCM) Industry - TCM Is Becoming Indispensable in the Portfolio30 Mar 2023
- China Shineway Pharmaceutical (2877.HK) - Some Points Worth the Attention03 Feb 2023
- China Shineway Pharmaceutical (2877HK)-Shineway Is Undervalued, but Downside Risk Is Hard to Control27 Sep 2022
x